Visacor

País: Nova Zelanda

Idioma: anglès

Font: Medsafe (Medicines Safety Authority)

ingredients actius:

Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin;  ;  ;  

Disponible des:

AstraZeneca Limited

Designació comuna internacional (DCI):

Rosuvastatin calcium 5.2 mg (= 5 mg rosuvastatin)

Dosis:

5 mg

formulario farmacéutico:

Film coated tablet

Composición:

Active: Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin       Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Yellow Iron oxide yellow as Opadry Yellow Lactose monohydrate as Opadry Yellow   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Yellow Triacetin as Opadry Yellow

Unidades en paquete:

Blister pack, Al/Al foil, 7 tablets

clase:

Prescription

tipo de receta:

Prescription

Fabricat per:

Lonza AG

indicaciones terapéuticas:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 7 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

Data d'autorització:

2009-07-31